China Targets Pharma Distribution Revamp Via New Good Supply Practices
This article was originally published in PharmAsia News
A China FDA official said the new good supply practices (GSP) has no target number for eliminating pharma distributors, but instead it aims to shift resources to large companies from outdated and smaller competitors.
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.